低中危前列腺癌单纯高剂量率近距离治疗:19 Gy单次与13.5 Gy两次随机II期试验9年更新疗效结果
该随机II期试验纳入170例低危或中危前列腺癌患者,比较27 Gy分2次(每次13.5 Gy,间隔一周)与单次19 Gy高剂量率近距离治疗单纯治疗的疗效,中位随访107个月。2次方案8年局部失败累积发生率11.2%,显著低于单次方案的35.9%(p < 0.001);单次方案肿瘤控制差,不被推荐。
要点
- 2次方案8年局部失败累积发生率11.2%,单次方案为35.9%(p < 0.001)。
- 2次方案8年中位PSA为0.08 ng/ml,单次方案为0.89 ng/ml。
- 单次19 Gy方案肿瘤学控制差,不被推荐。
核心结论
- 分2次给予13.5 Gy的高剂量率近距离治疗单纯治疗在8年时显示持续肿瘤控制且耐受良好。
- 单次单纯治疗肿瘤学控制差,不被推荐。
研究设计与样本
- 随机II期临床试验,纳入170例低危或中危前列腺癌患者,前列腺体积<60 cc且未使用雄激素剥夺治疗。
- 患者随机接受27 Gy分2次(间隔一周,每次13.5 Gy)或单次19 Gy高剂量率近距离治疗单纯治疗。
- 中位年龄65岁,中位随访107个月,中位基线PSA 6.35 ng/ml。
主要发现
- NCCN风险分组为低危19%、有利中危51%、不利中危30%。
- 8年中位PSA为2次组0.08 ng/ml vs 单次组0.89 ng/ml。
- 8年局部失败累积发生率为2次组11.2% vs 单次组35.9%(p < 0.001)。
- 8年远处失败发生率为2次组3.8% vs 单次组2.5%(p = 0.6)。
临床怎么用
- 原文结论指出单次19 Gy单纯治疗肿瘤学控制差,不被推荐。
- 原文结论指出分2次13.5 Gy方案在8年时显示持续肿瘤控制且耐受良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: High dose-rate (HDR) brachytherapy as a monotherapy is an accepted treatment for localized prostate cancer, but the optimal dose and fractionation schedule remain unknown. We report on the efficacy of a randomized Phase II trial comparing HDR monotherapy delivered as 27 Gy in 2 fractions vs. 19 Gy in 1 fraction with a median follow-up of 9 years. MATERIALS AND METHODS: Enrolled patients had low or intermediate-risk disease, <60 cc prostate volume and no androgen deprivation use. Patients were randomized to 27 Gy in 2 fractions delivered one week apart vs a single fraction of 19 Gy. RESULTS: 170 patients were randomized: median age 65 years, median follow-up 107 months and median baseline PSA 6.35 ng/ml. NCCN risk categories comprised low (19 %), favourable (51 %), and unfavourable intermediate risk (30 %). The median PSA at 8 years was 0.08 ng/ml in the 2-fraction arm vs. 0.89 ng/ml in the single-fraction arm. The cumulative incidence of local failure at 8 years was 11.2 % in the 2-fraction arm vs. 35.9 % in the single-fraction arm (p < 0.001). The incidence of distant failure at 8 years was 3.8 % in the 2-fraction arm and 2.5 % in the single-fraction arm (p = 0.6). CONCLUSIONS: HDR monotherapy delivered in two fractions of 13.5 Gy demonstrated a persistent cancer control rate at 8 years and was well-tolerated. Single-fraction monotherapy yielded poor oncologic control and is not recommended. These findings contribute to the ongoing discourse on optimal HDR monotherapy strategies for low and intermediate-risk prostate cancer.
引用
- Hudson JM, Loblaw A, McGuffin M, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update. Radiother Oncol. 2024. PMID: 38879130. doi:10.1016/j.radonc.2024.110381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。